Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic NK cells + rituximab + tafasitamab + interleukin-2
- Development stage
- Unknown
- Lead developer
- Case Comprehensive Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This investigational combination immunotherapy is being evaluated for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. The regimen consists of donor-derived (allogeneic) natural killer (NK) cells administered in conjunction with two monoclonal antibodies: rituximab, which targets the CD20 antigen, and tafasitamab, which targets the CD19 antigen. The NK cells serve as immune effector cells intended to enhance antibody-dependent cellular cytotoxicity (ADCC) against lymphoma cells coated with these antibodies. Interleukin-2 (IL-2) is co-administered to support the activation, survival, and proliferation of the infused NK cells. The treatment is typically preceded by a lymphodepleting conditioning regimen of fludarabine and cyclophosphamide to facilitate the persistence of the allogeneic cells.
- Other names
- Allogeneic NK cells with Rituximab and TafasitamabRituximab and Tafasitamab in Combination With Allogeneic NK Cells
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on allogeneic NK cells + rituximab + tafasitamab + interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic NK cells + rituximab + tafasitamab + interleukin-2.